Corporate Performance     

Published: September 15, 2024
Updated: September 15, 2024

Vaishali Pharma Ltd.

Rewards Shareholders with 1:1 Bonus, Eyes Global Leadership in PHARMA

There is good news for the shareholders of Vaishali Pharma (NSE – VAISHALI). The board of directors of the has recommended a liberal issue of bonus shares in the ratio of 1:1 (one bonus equity share for every equity share held by the shareholder on the record date to be announced shortly). Besides the compay has also announced a stock split, indication sub-division of 1 equity share of the face value of Rs. 10 into 5 equity shares of Rs. 2 each. The board decisions are subject to necessary regulatory and shareholders’ approval. The board decisions are aimed at rewarding existing shareholders, enhancing liquidity and expanding the shareholder base.

Commenting on the development, Mr. Atul Vasani, Chairman and Managing Director, Vaishali Pharma Ltd said, “We are proud to inform our stakeholders that the company is making significant strides in its long-term growth strategy, delivering excellent operational and financial results. Consideration of stock split and bonus shares are in line with the company’s vision to reward the shareholders and earn their long-lasting trust and confidence. This move will not only reward our existing shareholders for their continued support but also increase the company’s equity base, thereby enhancing liquidity. With a focus on growth and innovation, the company is making its mark through strategic initiatives, promising to become a significant presence in the evolving pharmaceutical sector.”

Established in 1989, Vaishali Pharma specializes in the manufacturing and marketing of a diverse range of pharmaceutical products, including APIs, formulations, surgical products, veterinary supplements, herbal items, nutraceuticals, and oncology products. The company’s portfolio serves both human and animal healthcare needs. The company has over 250 + formulation brands marketed in multiple countries and a robust pipeline of around 250 dossiers. The company’s synergistic collaboration with WHO-GMP manufacturing facilities is backed by an excellent rapport with clients. The company is one of the fastestgrowing and most versatile entity in the pharmaceutical industry. It has a strong presence in both the domestic and export markets and is currently supplying to all leading Indian and international companies.

As an emerging force, Vaishali Pharma is poised to contribute substantially to the pharmaceutical landscape in India. The company had recently announced the launch of its new brand “HealthE” for local online market. The first product in this lineup is HealthE Biotin and Multivitamin Gummies is a revolutionary product designed to enhance hair, skin, and overall health. These delectable gummies combine the power of biotin, essential vitamins, and natural extracts to support hair growth, promote radiant skin, and boost overall vitality. All the products launched are backed by food scientist. This exciting development is a testament to the company’s ongoing commitment to delivering health and wellness solutions that improve lives and promote lasting well-being. The company plans to add many more products in near future.

“Our venture into the Nutraceutical Products segment, in addition to our ongoing collaborations and alliances, is poised to serve as pivotal growth catalysts in the future. We eagerly anticipate the continuation of our journey towards excellence, with the utmost focus on delivering value to our stakeholders and making significant contributions to the enhancement of healthcare worldwide. Our unwavering dedication to innovation, commitment to maintaining high-quality standards, and the strategic expansion of our global footprint through valuable partnerships have been instrumental in driving our success”, added Mr. Vasani.